Product Information

PHENDIMETRAZINE ER 105 MG CAP is a generic product labeled by Acertis Pharmaceuticals, LLC, priced at $3.4049 per EA under NDC 72989040930. Its NADAC has been published 189 times since Apr 12, 2023.

FDA first approved this application before 1982.

The High Outlier badge above means this manufacturer's average price in the PHENDIMETRAZINE TARTRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

PHENDIMETRAZINE ER 105 MG CAP

PHENDIMETRAZINE TARTRATE
$3.4049per EA
High Outlier
DEA Schedule CIII

Strength

105 mg/1

NDC

72989040930

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

PHENDIMETRAZINE TARTRATE

Approval Type

New Drug (NDA)

FDA Application

NDA018074

FDA Approved

Before 1982

On Market Since

11/1/2022

Pharmacological Classes

Appetite Suppression
Increased Sympathetic Activity
Sympathomimetic Amine Anorectic

Price Statistics

The NADAC for PHENDIMETRAZINE ER 105 MG CAP has been published 189 times since Apr 12, 2023, and over the history we have for it it has risen 36.6%. The table below summarizes its recorded NADAC range and movement.

Current price$3.4049 per EA
All-time high$3.4075 (Nov 11, 2026)
All-time low$2.4773 (May 17, 2023)
52-week high$3.4075
52-week low$3.1369
Median price$2.8569
Average price$2.8714
Largest weekly change+15.1% (Apr 17, 2024)
Weeks tracked189
Tracking sinceApr 12, 2023

Price History

1W

-0.1%

1M

+0.7%

3M

+1.9%

6M

+7.3%

1Y

+8.4%

3Y

+36.7%

5Y

N/A

All

+36.6%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PHENDIMETRAZINE TARTRATE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of PHENDIMETRAZINE ER 105 MG CAP?

The current National Average Drug Acquisition Cost (NADAC) for PHENDIMETRAZINE ER 105 MG CAP, manufactured by Acertis Pharmaceuticals, LLC, is $3.4049 per EA (NDC 72989040930), effective Nov 18, 2026.

How has the price of PHENDIMETRAZINE ER 105 MG CAP changed over time?

Over the history we have for it, the NADAC for PHENDIMETRAZINE ER 105 MG CAP has risen 36.6%. It has been tracked across 189 weekly CMS publications since Apr 12, 2023.

What are the highest and lowest recorded NADAC prices for PHENDIMETRAZINE ER 105 MG CAP?

Since Apr 12, 2023, the NADAC for PHENDIMETRAZINE ER 105 MG CAP has ranged from a low of $2.4773 (May 17, 2023) to a high of $3.4075 (Nov 11, 2026), with a median of $2.8569 per EA.

Are there cheaper alternatives to PHENDIMETRAZINE ER 105 MG CAP?

No other NADAC-published product currently shares the active ingredient and strength of PHENDIMETRAZINE ER 105 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures PHENDIMETRAZINE ER 105 MG CAP?

PHENDIMETRAZINE ER 105 MG CAP (NDC 72989040930) is labeled by Acertis Pharmaceuticals, LLC, and CMS classifies it as a generic product.